[1]谢金平,邵 蓉.日本仿制药促进政策研究及启示[J].卫生经济研究,2020,(04):57-59,63.
　XIE Jin-ping,SHAO Rong.Research on Japanese Generic Drug Promotion Policy and Its Inspiration[J].Journal Press of Health Economics Research,2020,(04):57-59,63.
点击复制

日本仿制药促进政策研究及启示
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2020年04期
页码:
57-59,63
栏目:
他山之石
出版日期:
2020-04-02

文章信息/Info

Title:
Research on Japanese Generic Drug Promotion Policy and Its Inspiration
作者:
谢金平1; 邵 蓉1
1.中国药科大学国家药物政策与医药产业经济研究中心，江苏 南京 211198
Author(s):
XIE Jin-ping; SHAO Rong
National Pharmaceutical Policy and Pharmaceutical Industry Economic Research Center，China Pharmaceutical University，Nanjing Jiangsu 211198，China
关键词:
仿制药促进行动计划; 仿制药一致性评价; 仿制药替代率; 医保偿付政策
Keywords:
generic drug promotion action plan; generic drug consistency evaluation; generic drug substitution rate; medicare reimbursement policy
分类号:
R19
文献标志码:
A
摘要:
日本通过一系列仿制药促进政策，包括仿制药促进行动纲领、供给端仿制药质量保证措施、需求端医保偿付及宣传教育措施，使仿制药替代率大大提高。建议我国通过立法明确仿制药的使用，并从供给端角度加快推进仿制药一致性评价，提升仿制药质量；从需求端角度加强公众教育，提高对仿制药的认识，同时运用医保支付杠杆作用，激励和引导仿制药的使用。
Abstract:
Japan has adopted a series of generic drug promotion policies，including a generic drug promotion action plan，supply-side generic drug quality assurance measures，demand-side medical insurance reimbursement，and publicity and education measures，which have greatly improved the substitution rate of generic drugs. It is suggested that China adopt legislation to clarify the use of generic drugs，and accelerate the evaluation of generic drug consistency from the supply side to improve the quality of generic drugs；strengthen public education from the demand side，increase awareness of generic drugs，and use medical insurance pay leverage to stimulate and guide the use of generic drugs.

参考文献/References:

[1] Shafie A.A, Hassali M.A. Price comparison between innovator and generic medicines sold by community pharmacies in the state of Penang, Malaysia[J].Generic Med，2008（6）:35-42.
[2] Cabinet office. Basic Policy on Economic and Fiscal Management and Reform 2015[EB/OL]. [2015-06-30] .https://nsearch.cao.go.jp/cao/search.x?q=Basic+Policy+on+Economic+and+Fiscal+Management+and+Reform+2015&submit=search&mode_ja_cao=ja_ cao&page=1&ie=UTF-8&tmpl=en.
[3] 谢沐风. 对《日本版橙皮书——溶出一致、临床疗效一致》的解读——兼论我国口服固体制剂仿制药质量评价[J]. 药品评价, 2017(4):20-23，60.
[4] 郭志鑫, 南楠, 乔利涛, 等. 日本蓝皮书的介绍及启示[J]. 中国药事, 2018, 32(4):37-44.
[5] Kuribayashi R , Matsuhama M , Mikami K . Regulation of Generic Drugs in Japan: the Current Situation and Future Prospects[J]. The AAPS Journal,2015, 17(5):1312-1316.
[6] Iizuka T, Kubo K. The generic drug market in Japan: will it finally take off? Health Econ Policy Law，2010，6(3)：369-389 .
[7] 厚生劳动省. Promotion of the Use of Generic Drugs[EB/OL]. [2012-09] . https://www.mhlw.go.jp/english/policy_report/2012/09/120921.html.
[8] Jakovljevic Mihajlo B,Nakazono Sanae,Ogura Seiritsu. Contemporary generic market in Japan - key conditions to successful evolution[J]. Expert review of pharmacoeconomics & outcomes research,2014,14(2).
[9] 国务院办公厅.关于开展仿制药质量和疗效一致性评价的意见[EB/OL]. [2016-03-05].www.gov.cn/zhengce/content/2016-03/05/ content_5049364.htm.
[10] 国务院办公厅.关于进一步改革完善药品生产流通使用政策的若干意见[EB/OL]. [2017-02-09].www.gov.cn/zhengce/content/2017-02/09/content_5166743.htm.
[11] 国务院办公厅.关于改革完善仿制药供应保障及使用政策的意见[EB/OL]. [2018-04-03].www.gov.cn/zhengce/content/2018- 04/03/content_5279546.htm.
[12] 颜耀东,黄晓洁,王楠.药品质量标准与药品质量评价相关性的探讨[J].中国药房,2007(34):2650-2652.
[13] Bora Lichanda（李常德）. 替米沙坦片仿制药与原研药质量差异研究[D].中南大学,2013.
[14] 江文明, 刘茜, 金薇,等. 比卡鲁胺片仿制药和原研药的质量比对[J]. 中国医药工业杂志, 2018, 49(10):99-105.
[15]李新刚, 赵志刚. 从临床疗效角度谈原研药和仿制药的区别[J]. 药品评价, 2013(12):8-12.

相似文献/References:

[1]罗雪燕,赖 寒,王梦媛,等.省级药品集中带量采购模式对比研究[J].卫生经济研究,2022,39(5):7.
　LUO Xue-yan,LAI Han,WANG Meng-yuan,et al.Comparative Study on the Model of Centralized Volume-Based Procurement of Drugs at the Provincial Level[J].Journal Press of Health Economics Research,2022,39(04):7.

更新日期/Last Update: 2020-04-02